Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.62 |
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | ECE1 | P42892 | 4/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593374 | 0.97 | GHSR (0.64) | GHSRACE | |
| SCHEMBL30051742 | 0.91 | ACE (0.68) | ACEECE1ERAP2LTA4HP2RY14 | |
| SCHEMBL31593292 | 0.90 | GHSR (0.57) | GHSRACE | |
| SCHEMBL29925186 | 0.90 | GHSR (0.60) | GHSRACEECE1ERAP2 | |
| SCHEMBL31018785 | 0.90 | ACE (0.62) | GHSRACEECE1ERAP2ALOX15 | |
| SCHEMBL29924977 | 0.90 | GHSR (0.60) | GHSRACEECE1ERAP2 | |
| SCHEMBL30921655 | 0.90 | GHSR (0.60) | GHSRACEECE1ERAP2ALOX15 | |
| SCHEMBL31468798 | 0.90 | GHSR (0.60) | GHSRACEECE1ERAP2 | |
| SCHEMBL31593361 | 0.90 | ACE (0.59) | GHSRACEECE1ERAP2LTA4H | |
| SCHEMBL29701396 | 0.90 | GHSR (0.55) | GHSRACELTA4HP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | TORQUE THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220195071-A1 | IMMUNOTHERAPEUTIC COMPOSITIONS AND USE THEREOF | TORQUE THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195071-A1 | IMMUNOTHERAPEUTIC COMPOSITIONS AND USE THEREOF | IL2, CD47, IFNG | GHSR 3849/4885ACE 4259/4885ECE1 2952/4885 |
| US-11471490-B2 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | CD4, ICOS, IL2 | GHSR 3241/4885ACE 3666/4885ECE1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.